Efficacy and Safety of Tirzepatide Once Weekly versus Placebo for the Treatment of Obesity
and Weight-Related Comorbidities in Adolescents: A Randomized, Double-Blind, Placebo-
Controlled Trial

Further information

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial: 5 Independent Sub-studies of Setmelanotide in Patients with POMC, PCSK1, LEPR, SRC1, SH2B1, and PCSK1 N221D Gene Defects in the Melanocortin-4 Receptor Pathway
Further information

An interventional, randomised, double-blind, parallel group, placebo-controlled, multi-national clinical study period.
Long-term safety and efficacy of semaglutide s.c. once-weekly on weight management in children and adolescents (aged 6 to <18 years) with obesity or overweight
Further information
 

Long Term Extension Trial of Setmelanotide (RM-493) for Patients who have completed a trial of Setmelanotide for the treatment of obesity associated with genetic defects upstream of the MC4 Receptor in the Leptin-melanocortin Pathway
Further information
 

A Phase 2, Two-Stage (Open-Label Run-in Followed by Randomized Withdrawal), Double-Blind, Placebo-Controlled Study of Setmelanotide in Patients with Specific Gene Variants in the Melanocortin-4 Receptor Pathway
Further information
 

A Phase 3, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Setmelanotide in Patients with Acquired Hypothalamic Obesity

A Trial Comparing the Effect and Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® in Children With Growth Hormone Deficiency
Further information
 

The study is a post-authorization, prospective, voluntary registry of patients treated with commercial metreleptin.
Further information

A Registry of Patients with Biallelic Pro-Opiomelanocortin (POMC), Proprotein Convertase Subtilisin/Kexin Type 1 (PCSK1), or Leptin Receptor (LEPR) Deficiency Obesity, or Bardet-Biedl Syndrome (BBS), Treated with Setmelanotide

Observational study on the treatment of patients with paediatric indications such as growth hormone deficiency (GHD), small for gestational age (SGA), Ullrich-Turner syndrome (UTS) and prepubertal patients with chronic kidney disease (CRI) as well as replacement therapy in adults with pronounced growth hormone deficiency (AGHD) with rh-GH (recombinant human growth hormone) Saizen®.

• ECLip Registry
• iDSD and DSD Registry
• Registry for patients with hypothyroidism
• Registry for patients with adrenogenital syndrome (AGS)
• Diabetes patient progress documentation (DPV)
• Structured pre- and aftercare programme after bariatric surgery
  Register for patients with extreme obesity

• Diabetes and social jet lag
•  BMBF - JA Study
• Ulm Paediatric Study
• Pfizer Registry of Outcomes in Growth hormone RESearch (PROGRES)

A 52-week randomized, double-blind, placebo controlled, multi-center Phase 2b study with a 52-week blinded extension assessing safety and efficacy of frexalimab, a CD40L antagonist
monoclonal antibody, for preservation of pancreatic β-cell function in adults and adolescents with newly diagnosed type 1 diabetes on insulin therapy
 

A randomized, double-blind, 2-arm, Phase 3 study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with newly diagnosed Stage 3 Type 1 Diabetes (T1D)

Efficacy of Semaglutide s.c. once-weekly on Weight Loss and Management in Adolescents with Monogenic Obesity in Clinical Practice

Weight maintenance in adolescents with obesity; long-term treatment with semaglutide 2.4mg s.c. once-weekly.

Open-label, Phase 3b study to evaluate effectiveness, safety and pharmacokinetic parameters of metreleptin in patients under 6 years of age with generalised lipodystrophy and associated diabetes mellitus and/or hypertriglyceridaemia.

A 24-Month, Multi-Centre, Open Label Phase IV Post Authorisation Efficacy Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily Subcutaneous Metreleptin Treatment in Patients with Partial Lipodystrophy.

Medical device study for children with diabetes.